Fruquintinib · Fruzaqla / Elunate
Small molecule
Also known as HMPL-013
Evidence outlook
Approved: Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Renal Cell Carcinoma · Phase 3 · investigational in the US · under NMPA reviewEndometrial Cancer · Phase 3 · investigational in the US
Also approved (3)
- Fruquintinib in combination with sintilimab, second-line advanced renal cell carcinoma after prior VEGFR-TKI therapy
- Treatment of unresectable advanced or recurrent colon or rectal cancer that has progressed after cancer chemotherapy
- Monotherapy for adults with metastatic colorectal cancer previously treated with available standard therapies who progressed on or are intolerant to trifluridine-tipiracil or regorafenib
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
FRESCO-2 NCT04322539 · Colorectal Cancer This was a randomized, quadruple-blind, placebo-controlled trial involving 691 participants, with overall survival as the primary clinical endpoint. The primary comparison favored fruquintinib and was statistically significant: median overall survival was 7.4 versus 4.8 months, with hazard ratio 0.662 and p<.001. Registry: NCT04322539 | 3 | Overall Survival (OS) (From date of randomization to death from any cause (up to 22 months)) 2022-07-29 | Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001 | Reliable signal | link ↗ |
View 1 more trial
FRESCO NCT02314819 · Colorectal Cancer FRESCO randomised 416 Chinese patients with metastatic colorectal cancer after at least two lines of chemotherapy 2:1 to fruquintinib or placebo, double-blind. The primary endpoint, overall survival, was met: median 9.3 vs 6.6 months, HR 0.65 (95% CI 0.51 to 0.83). The figures are from the JAMA 2018 publication; the registry has no posted results. Result from the peer-reviewed publication (Li et al., JAMA 2018); the registry has no posted results. Registry: NCT02314819 | 3 | overall survival (from randomization until death due to any cause, assessed up to 2 year) 2017-01 | Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (105)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (21)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (4)
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (4)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Appears in other studies (4)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other VEGFR1/2/3 drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Renal Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Fruquintinib (Fruzaqla / Elunate): this drug | Phase 3 | Small molecule | VEGFR1/2/3 | not yet graded | No reviewed efficacy summary in this indication | |
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Avelumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Axitinib | Approved | Small molecule | VEGFR1/2/3 | Partial signal | NCT02684006: Primaries in PD-L1-positive patients, avelumab + axitinib vs sunitinib: PFS (BICR) median 13.8 vs 7.2 months, hazard ratio 0.61 (95% CI 0.475 to 0.790), p=0.0001, met; OS median 43.2 vs 36.2 months, hazard ratio 0.86 (95% CI 0.701 to 1.057), p=0.1509, not significant (CT.gov posted results). | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Belzutifan (Welireg) | Approved | Small molecule | HIF-2alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | No reviewed efficacy summary in this indication | |
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT01668784: Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pazopanib (Votrient) | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | Featured results are non-efficacy only in this race | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02811861: Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11) NCT04704219: Objective Response Rate (ORR) (Up to approximately 47 months): Pembrolizumab + Lenvatinib 50.6 Percentage of participants (95% CI 42.6 to 58.7) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Savolitinib (Orpathys) | Phase 3 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ciforadenant | Phase 1/2 | Small molecule | adenosine A2A | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(55 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Fruzaqla / Elunate (Fruquintinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (8)
December 2026 (8)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2027 (28)
January 2027 (2)
March 2027 (2)
May 2027 (1)
What to watch
June 2027 (3)
What to watch
What to watch
What to watch
July 2027 (3)
What to watch
What to watch
What to watch
August 2027 (3)
What to watch
What to watch
What to watch
September 2027 (1)
What to watch
October 2027 (4)
What to watch
What to watch
What to watch
What to watch
November 2027 (3)
What to watch
What to watch
What to watch
December 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (11)
February 2028 (1)
What to watch
March 2028 (2)
What to watch
What to watch
April 2028 (2)
October 2028 (3)
What to watch
What to watch
What to watch
December 2028 (3)
What to watch
What to watch
What to watch
2029 (4)
2030 (3)
September 2030 (1)
What to watch
November 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (1)
March 2031 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent